Drug Discovery

#Biopharma #Drug discovery #Life sciences #R&D

Abcam opens new US site

Abcam has opened a new site in Waltham, MA. The facility is a central part of Abcam’s growth in the US and will serve as a hub for its R&D and commercial activities in the region. “Abcam’s first step toward global expansion was in 2003 at Kendall Square.  Since then,… Read More

#News

#AI / data analytics / healthtech / informatics #Biopharmaceuticals #Drug delivery #Drug development #Pharma #Pharmaceuticals

Half of pharma believes AI can help bring new drugs to market faster

New research reveals that 50% of European and US pharmaceutical manufacturing companies know artificial intelligence (AI) can help bring new drugs to market more rapidly and securely, but 96% face challenges with using it to derive value from their data. 49% of all executives surveyed say their company has no… Read More

#News

#Assays #Drug delivery #Drug discovery #In vitro

Gentronix acquires Big Blue transgenic mutation assay models

UK-based Contract Research Organisation (CRO) Gentronix is set to expand its genetic toxicology capabilities and accelerate its growth following acquisition of the Big Blue transgenic mutation assay models. The acquisition ensures the continuing market provision of the Big Blue transgenic assays for companies requiring mutagenicity assessment under the OECD 488… Read More

#News

Cannabis plant
#Cannabinoid #Clinical trials #Drug development #Drug discovery

Agreement will speed up cannabinoid drug development

Oxford Cannabinoid Technologies (OCTP) and Evotec have entered into a service agreement to expedite the development of OCTP’s lead compound, OCT461201, a selective cannabinoid receptor Type 2 agonist, towards Phase I clinical trials. This Phase I clinical trial will be aimed at demonstrating the safety and tolerability of the drug… Read More

#News

#Anti-virals #Covid-19 #Drug development

Large-scale drug analysis reveals potential new Covid-19 antivirals

Researchers at the Francis Crick Institute and University of Dundee have screened thousands of drug and chemical molecules and identified a range of potential antivirals that could be developed into new treatments for Covid-19 or in preparation for future coronavirus outbreaks. While Covid-19 vaccines are being rolled out, there are… Read More

#Editor's Choice #News #Trending News

#Drug development #Drug discovery #Immunobiology #Research

Stem cells use same method as plants and insects to protect against viruses

Researchers at the Francis Crick Institute have found a vital mechanism, previously thought to have disappeared as mammals evolved, that helps protect mammalian stem cells from RNA viruses such as SARS-CoV-2 and Zika virus. The scientists suggest this could one day be exploited in the development of new antiviral treatments. Read More

#News

#Biomarkers #Drug development #Drug discovery #Neuroscience #Novel therapeutics #Therapeutics

Biomarker company raises £2.6 million for neuroscience drugs

Monument Therapeutics has raised £2.6 million in seed funding to spin out of Cambridge Cognition and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel… Read More

#News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (5 – 9 July)

News round-up by DDW’s Megan Thomas for 5 – 9 July We know that innovation is key in the drug discovery and development sector. DDW’s Megan Thomas rounds up her top five stories this week which highlight the industry’s on-going work to create breakthrough therapeutics for global wellbeing. Read More

#News #Trending News

#Biomarkers #Drug delivery #Drug discovery #Drug screening #High throughput screening #Webinar

Webinar: Enabling biomarker discovery and screening

Multiplex assays allow researchers to measure multiple biomarkers simultaneously, offering the advantage of harvesting more insightful data to inform better decision-making, accelerate research, and increase the probability of discovery. Enabling biomarker discovery and screening with FirePlex Multiplexed Assays features the expertise of Dr Paul Wylie. In this webinar with… Read More

#News

#Biologics / Biotechnology #Bioscience #Biotechnology #Drug delivery #Drug development #Drug discovery

Switzerland: punching above its weight as global biotech hub

Listen to this article on the DDW Podcast:   To understand Switzerland’s continued success in the biotech sector and gain personal insights, Lu Rahman spoke to Michael Altorfer (CEO of the Swiss Biotech Association), Jan Lucht (Head of Biotechnology, scienceindustries), Claude Joris (Secretary General, BioAlps), and Carole Delauney (Business Development… Read More

#Editor's Choice #Exclusive Content #Market Reports #News

#Biosciences #Biotherapeutics #Drug design #Drug development #Drug discovery

New approach will help identify drugs that can ‘glue’ proteins together

A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Drug screening #High throughput screening

What will this NIGMS grant mean for combatting rare diseases?

Sinopia Biosciences has been awarded a grant from the National Institute of General Medical Sciences (NIGMS), as part of the National Institutes of Health, to further develop and validate their proprietary metabolomics-based high-throughput screening (HTS) platform with an initial focus on rare diseases. To date, Sinopia has received nearly $8… Read More

#News

#Covid-19 #Drug delivery #Drug development #Drug discovery #Life sciences #Regulatory #Technology

How will UK life sciences vision impact medicine development and research?

The new UK Life Sciences Vision, developed with businesses and experts in the field, outlines seven critical missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia. These missions will focus on preventing, diagnosing,… Read More

#News #Regulatory #Trending News

#Clinical trials #Drug development #Drug discovery #Research #Sclerosis

Gesynta Pharma announces significant progress across new drug candidate

Gesynta Pharma has announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration (FDA) for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across… Read More

#News

#Covid-19 #Drug development #Drug discovery #Drug targets

Targeted treatments for respiratory infections

A new experimental model that more accurately replicates the impact of respiratory infections on the lungs and upper airways has been developed through an SME and academic partnership supported by the Infection Innovation Consortium (iiCON). Led by Founding Director, Professor Janet Hemingway CBE of Liverpool School of Tropical Medicine, iiCON… Read More

#News